ADRIAN ADAMS - 14 Feb 2023 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC (IMPL)

Role
COB, CEO and President, Director
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Issuer symbol
IMPL
Transactions as of
14 Feb 2023
Transactions value $
$0
Form type
4
Filing time
16 Feb 2023, 17:19:35 UTC
Previous filing
15 Jul 2022
Next filing
08 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPL Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 14 Feb 2023 Common Stock 200,000 $2.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.